234 results
6-K
EX-99.1
BLRX
Bioline Rx Ltd
17 Apr 24
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4
7:12am
medication and local treatments post-dose, as needed.
Tumor Cell Mobilization in Patients with Leukemia: For the purpose of hematopoietic stem cell (HSC
6-K
EX-10.2
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the 1934 Act. No prior inability to exercise this Warrant pursuant … of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation
6-K
EX-10.1
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors … established for such purpose for services rendered to the Company; provided that any securities so issued to consultants shall only be issued
424B5
BLRX
Bioline Rx Ltd
1 Apr 24
Prospectus supplement for primary offering
10:30am
or distribution of this prospectus supplement in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside … with the SEC on March 26, 2024, and any amendment or report filed for the purpose of further updating that description.
We also incorporate by reference
20-F/A
2023 FY
EX-2.1
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
securities or securities that may be realized as shares up to the limit of the Company’s registered capital. For the purpose of calculating the limit … in the Company.
Any Request to Convene must specify the goals for whose purpose the meeting is to be convened, and shall be signed by those requesting
20-F/A
0xrz7 3klq13uc
26 Mar 24
Annual report (foreign) (amended)
4:57pm
6-K
EX-1
78wo1 klv4
16 Feb 24
Current report (foreign)
7:07am
S-8
cj2s9n2yy4pc5wm04sz
29 Dec 23
Registration of securities for employees
4:20pm
F-3
EX-5.2
qtrr9mih
29 Dec 23
Shelf registration (foreign)
4:15pm
F-3
2k4a6wwm4e7165ak
29 Dec 23
Shelf registration (foreign)
4:15pm
6-K
EX-99
uthdba9o q2ae
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
zsnqalai6ov 4d3p7le4
11 Sep 23
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple
7:07am
6-K
EX-99
473wfvdcm3y2bm1uj
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
iu6q4asf10 nnmii5a6
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-99
qwq79t1
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-99
tfkvd
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
6-K
EX-99
5dv2vz
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am